Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Sep 10;209(5):2191–2202. doi: 10.1111/bjh.70822

Optimizing cord blood unit selection to improve survival after single‐unit unrelated cord blood transplantation for adult myelodysplastic syndrome

Takaaki Konuma 1,✉, Machiko Fujioka 2, Kyoko Fuse 3, Tatsuya Suwabe 3, Hiroki Hosoi 4, Naoyuki Uchida 5, Masatsugu Tanaka 6, Kazuto Ogura 7, Satoshi Takahashi 8, Makoto Onizuka 9, Takeshi Maeda 10, Noriko Doki 11, Yasufumi Uehara 12, Atsushi Wake 13, Masatoshi Sakurai 14, Naoyuki Anzai 15, Toshimitsu Ueki 16, Yoshiko Matsuhashi 17, Koji Kawamura 18, Fumihiko Ishimaru 19, Junya Kanda 20, Marie Ohbiki 21,22, Yoshiko Atsuta 21,22, Hidehiro Itonaga 23
PMCID: PMC13748397  PMID: 42717739

Summary

Unrelated cord blood transplantation (CBT) is an important alternative donor option for adult patients with myelodysplastic syndrome (MDS); however, the prognostic significance of cord blood unit characteristics following CBT remains unclear and may vary according to disease risk. We conducted a nationwide retrospective study of 1767 adult patients with MDS who underwent first single‐unit CBT between 1999 and 2023, including 529 patients with low‐risk and 1238 with high‐risk disease at transplantation. Cord blood unit characteristics were not significantly associated with disease‐free survival (DFS) in patients with low‐risk MDS. In contrast, in patients with high‐risk MDS, higher cryopreserved cluster of differentiation (CD)34+ cell dose and higher colony‐forming unit–granulocyte/macrophage dose were associated with improved DFS, whereas human leucocyte antigen (HLA) serological one‐locus mismatch and female‐to‐male donor–recipient sex mismatch were independently associated with inferior DFS. Restricted cubic spline Cox regression demonstrated a significant non‐linear association between CD34+ cell dose and DFS, as well as relapse, in high‐risk MDS. These findings demonstrate that the prognostic impact of cord blood unit characteristics after single‐unit CBT differs according to MDS risk status and support a risk‐adapted approach to cord blood unit selection, particularly for patients with high‐risk MDS.

Keywords: CD34+ cells, colony‐forming unit–granulocyte/macrophage, cord blood transplantation, HLA mismatch, myelodysplastic syndrome

INTRODUCTION

Allogeneic haematopoietic stem cell transplantation (HSCT) is one of the most effective curative treatment options for myelodysplastic syndrome (MDS). However, because MDS predominantly affects older adults, identifying a suitable donor remains a major challenge. Recent studies have demonstrated that outcomes using alternative unrelated donors, including cord blood, are not inferior to those achieved with matched related donor HSCT in patients with MDS. 1 , 2 , 3 , 4 , 5 , 6 In Japan, the annual number of unrelated cord blood transplantations (CBTs) has increased markedly since the 2000s, particularly among adult patients with MDS. 7 , 8 , 9 Therefore, CBT represents an important alternative donor source in this population.

Optimal cord blood unit selection has traditionally been based on cryopreserved total nucleated cell (TNC) dose and human leukocyte antigen (HLA) compatibility. 10 , 11 More recently, cryopreserved cluster of differentiation (CD)34+ cell dose and colony‐forming unit–granulocyte/macrophage (CFU‐GM) dose have been reported to be better predictors of neutrophil engraftment than TNC dose in single‐unit CBT across heterogeneous cohorts with varying disease types and statuses. 8 , 9 , 12 , 13 , 14 , 15 , 16 In addition, higher‐resolution human leucocyte antigen (HLA) allele‐level matching has been shown to influence neutrophil engraftment and disease relapse in patients with acute leukaemia and MDS undergoing single‐unit CBT. 14 , 17 , 18 , 19 However, the prognostic impact of cord blood unit characteristics and HLA compatibility may vary depending on disease type, disease status and recipient age. To date, there is limited evidence that optimizing cord blood unit selection improves clinical outcomes specifically in patients with MDS. Moreover, the impact of these graft characteristics may differ between low‐risk and high‐risk disease. To address this gap, we conducted a retrospective nationwide study to evaluate the prognostic significance of cord blood unit characteristics in a large cohort of adult patients with low‐risk and high‐risk MDS undergoing single‐unit CBT in Japan.

METHODS

This retrospective study was conducted by the Adult MDS Working Group of the Japanese Society for Transplantation and Cellular Therapy (JSTCT). Data were obtained from the Transplant Registry Unified Management Program (TRUMP) database maintained by the Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT) and JSTCT. 20 , 21 Eligible patients were those aged ≥16 years with MDS who underwent single‐unit CBT as their first allogeneic HSCT between 1999 and 2023 in Japan. Patients lacking data on cryopreserved TNC dose, CD34+ cell count or CFU‐GM were excluded. In addition, patients without available classification according to the French–American–British (FAB) or World Health Organization (WHO) classification at the time of transplantation, or those diagnosed with chronic myelomonocytic leukaemia, were excluded. A total of 1767 patients met the eligibility criteria and were included in the analysis. This study was approved by the Adult MDS Working Group of the JSTCT and the institutional review board of the Institute of Medical Science, The University of Tokyo (approval number: 2025‐48‐0926). Details for methods are provided in the Supporting Information. 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34

RESULTS

Patient and transplantation characteristics

A total of 1767 adult patients with MDS who underwent single‐unit CBT were included in this study, comprising 529 patients with low‐risk and 1238 with high‐risk disease (Table 1). Compared with the low‐risk group, the high‐risk group had a higher proportion of male recipients (p = 0.013), de novo MDS (p = 0.011), higher International Prognostic Scoring System (IPSS) risk at diagnosis (p < 0.001), higher revised IPSS (IPSS‐R) risk at diagnosis (p < 0.001) and sex‐matched transplants (p = 0.028). The median age at CBT was slightly higher in the high‐risk group (60 vs. 59 years; p = 0.011). Recipient body weight, Eastern Cooperative Oncology Group performance status, Hematopoietic Cell Transplantation–Specific Comorbidity Index, anti‐HLA antibody status, conditioning intensity, graft‐versus‐host disease (GVHD) prophylaxis, anti‐thymocyte globulin (ATG) use and year of transplantation were comparable between the two groups. Cytogenetic risk distribution at diagnosis was also similar.

TABLE 1.

Characteristics of patients and cord blood transplantations based on disease status at CBT.

Variables Low‐risk High‐risk p‐value
Number of patients 529 1238
Recipient age at CBT, median (IQR) years 59 (49–65) 60 (52–66) 0.011
Recipient age at CBT category
<60 years 275 (52.0%) 582 (47.0%) 0.061
≥60 years 254 (48.0%) 656 (53.0%)
Recipient body weight, median (IQR) kg 58.0 (50.4–65.0) 58.0 (50.5–65.0) 0.882
Recipient gender
Female 200 (37.8%) 392 (31.7%) 0.013
Male 329 (62.2%) 846 (68.3%)
ECOG PS at CBT
0–1 486 (93.1%) 1113 (90.8%) 0.134
2–4 36 (6.9%) 113 (9.2%)
Missing 7 12
HCT‐CI
0–2 378 (75.8%) 893 (77.9%) 0.338
≥3 121 (24.2%) 253 (22.1%)
Missing 30 92
Anti‐HLA antibody
Negative 333 (71.6%) 791 (73.2%) 0.534
Positive 132 (28.4%) 290 (26.8%)
Missing 64 157
Donor‐specific anti‐HLA antibody (DSA) among positive anti‐HLA antibody
DSA negative 119 (90.2%) 270 (93.1%) 0.329
DSA positive 13 (9.8%) 20 (6.9%)
Conditioning regimen
MAC 281 (53.1%) 695 (56.1) 0.251
RIC 248 (46.9%) 543 (43.9)
GVHD prophylaxis
CI + MTX 289 (54.6%) 667 (53.9%) 0.794
Others 240 (45.4%) 571 (46.1%)
ATG
No use of ATG 495 (93.6%) 1166 (94.2%) 0.662
Use of ATG 34 (6.4%) 72 (5.8%)
Year of CBT
1999–2016 251 (47.4%) 598 (48.3%) 0.755
2017–2023 278 (52.6%) 640 (51.7%)
Disease type
De novo 457 (86.6%) 1123 (90.7%) 0.011
Secondary 71 (13.4%) 115 (9.3%)
IPSS at diagnosis <0.001
Low 46 (9.7%) 41 (3.7%)
Intermediate‐1 211 (44.4%) 231 (21.1%)
Intermediate‐2 148 (31.2%) 453 (41.4%)
High 70 (14.7%) 370 (33.8%)
Missing data 54 143
IPSS‐R at diagnosis <0.001
Very low 9 (4.2%) 7 (1.4%)
Low 25 (11.7%) 24 (4.9%)
Intermediate 60 (28.2%) 86 (17.6%)
High 61 (28.6%) 141 (28.8%)
Very high 58 (27.2%) 231 (47.2%)
Missing data 316 749
Cytogenetic risk at diagnosis
Good 178 (34.2%) 404 (33.3%) 0.618
Intermediate 116 (22.3%) 253 (20.8%)
Poor 226 (43.5%) 557 (45.9%)
Missing 9 24
Cryopreserved TNC dose, median (IQR) × 107/kg 2.63 (2.28–3.10) 2.59 (2.23–3.15) 0.387
<2.00 40 (7.6%) 122 (9.9%) 0.242
2.00–2.49 184 (34.8%) 429 (34.8%)
2.50–2.99 149 (28.2%) 304 (24.6%)
≥3.00 155 (29.4%) 379 (30.7%)
Missing 1 4
Cryopreserved CD34+ cell dose, median (IQR) × 105/kg 0.81 (0.61–1.15) 0.83 (0.61–1.10) 0.745
< 0.60 125 (23.6%) 284 (23.0%) 0.332
0.60–0.89 186 (35.2%) 425 (34.4%)
0.90–1.19 103 (19.5%) 286 (23.2%)
≥1.20 115 (21.7%) 240 (19.4%)
Missing 0 3
Cryopreserved CFU‐GM dose, median (IQR) × 103/kg 23.6 (16.5–33.3) 24.2 (17.4–33.0) 0.454
<15.0 96 (19.5%) 196 (17.3%) 0.595
15.0–24.9 176 (35.7%) 410 (36.1%)
25.0–34.9 110 (22.3%) 281 (24.8%)
≥35.0 111 (22.5%) 248 (21.9%)
Missing 36 103
HLA‐A, ‐B, ‐DR serum mismatch
0 47 (8.9%) 91 (7.4%) 0.543
1 164 (31.0%) 388 (31.4%)
2 318 (60.1%) 756 (61.2%)
Missing 0 3
HLA‐A, ‐B, ‐C, ‐DR allele mismatch
0–1 53 (12.8%) 106 (10.9%) 0.846
2 76 (18.4%) 175 (18.0%)
3 140 (33.8%) 349 (36.0%)
4 100 (24.2%) 230 (23.7%)
≥5 45 (10.9%) 110 (11.3%)
Missing 115 268
Sex incompatibility
Match 217 (43.5) 569 (49.6) 0.028
Male to female 109 (21.8) 196 (17.1)
Female to male 173 (34.7) 382 (33.3)
Missing 30 91
ABO incompatibility
Match 169 (31.9) 410 (33.1) 0.823
Minor mismatch 157 (29.7) 341 (27.6)
Major mismatch 122 (23.1) 298 (24.1)
Bidirectional mismatch 81 (15.3) 188 (15.2)
Missing 0 1
Duration from diagnosis to CBT, median (IQR) days 247 (148–725.5) 183 (110–343) <0.001

Note: The p‐values in bold are statistically significant (<0.05).

Abbreviations: ATG, anti‐thymocyte globulin; CBT, cord blood transplantation; CFU‐GM, colony‐forming unit granulocyte‐macrophage; CI, calcineurin inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; GVHD, graft‐versus‐host disease; HCT‐CI, Hematopoietic Cell Transplantation‐Specific Comorbidity Index; HLA, human leucocyte antigen; IPSS, International Prognostic Scoring System; IPSS‐R, revised International Prognostic Scoring System; IQR, interquartile range; MAC, myeloablative conditioning; MTX, methotrexate; RIC, reduced‐intensity conditioning; TNC, total nucleated cell.

Regarding graft characteristics, there were no significant differences in cryopreserved TNC dose, CD34+ cell dose or CFU‐GM dose when analysed as either continuous or categorical variables. HLA mismatch at both serological and allelic levels was comparable between groups, and no significant differences were observed in ABO incompatibility. The interval from diagnosis to CBT was significantly longer in the low‐risk group than in the high‐risk group (median, 247 vs. 183 days; p < 0.001).

Disease‐free survival and overall survival

In the univariate analysis using the log‐rank test, disease‐free survival (DFS) and overall survival (OS) did not significantly differ according to cord blood characteristics and cord blood‐recipient compatibility in the low‐risk group, whereas CD34+ cell dose (p = 0.007 for DFS, p = 0.007 for OS), HLA serum mismatch (p = 0.016 for DFS, p = 0.014 for OS) and sex compatibility (p = 0.005 for DFS, p = 0.014 for OS) were significantly associated with DFS and OS in the high‐risk group (Figure 1, Figures S1 and Figure S2). In high‐risk MDS, the unadjusted probability of DFS at 3 years differed significantly between the quartile values of CD34+ cell dose (34.4% [95% confidence interval (CI), 29.0%–39.9%] in CD34+Q1, 38.3% [95% CI, 32.6%–44.1%] in CD34+Q2, 42.0% [95% CI, 36.3%–47.6%] in CD34+Q3 and 43.4% [95% CI, 37.4%–49.1%] in CD34+Q4) (Figure 1B). The unadjusted probability of DFS at 3 years differed significantly between the sex compatibility (42.5% [95% CI, 38.2%–46.6%] in sex match group, 46.1% [95% CI, 38.6%–53.4%] in male donor to female recipient group and 33.7% [95% CI, 28.7%–38.7%] in female donor to male recipient group) (Figure 1E). The unadjusted probability of DFS at 3 years differed significantly between the HLA serum mismatch (50.8% [95% CI, 39.4%–61.1%] in HLA serum match group, 35.3% [95% CI, 30.3%–40.3%] in HLA serum one mismatch group, 40.6% [95% CI, 37.0%–44.3%] in HLA serum two mismatch group) (Figure S2A).

FIGURE 1.

FIGURE 1

The probability of disease‐free survival following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

In multivariable analysis, continuous TNC dose (hazard ratio [HR] 0.89, 95% CI 0.80–0.98), higher CD34+ cell dose 0.61–0.81 [Q2] (HR 0.80, 95% CI 0.66–0.98), 0.82–1.10 [Q3] (HR 0.75, 95% CI 0.61–0.92), ≥1.11 [Q4] × 105/kg (HR 0.69, 95% CI 0.56–0.85), higher CFU‐GM ≥33.1 [Q4] × 103/kg (HR 0.72, 95% CI 0.58–0.89) and continuous CFU‐GM dose (HR 0.99, 95% CI 0.98–0.99) were significantly associated with better DFS in the high‐risk group. By contrast, HLA serum one mismatch (HR 1.18, 95% CI 1.01–1.38), and female donor to male recipient (HR 1.19, 95% CI 1.00–1.40) were significantly associated with poorer DFS in the high‐risk group. There was no significant variable associated with DFS and OS in the low‐risk group (Figure 2A, Figure S3A).

FIGURE 2.

FIGURE 2

Forest plots of adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for treatment failure (A) and for relapse (B) according to cord blood characteristics following single‐unit CBT for low‐risk and high‐risk MDS.

Restricted cubic spline analyses demonstrated that higher TNC and CD34+ cell doses were significantly associated with improved DFS and OS in the high‐risk group, exhibiting clear non‐linear relationships. CFU‐GM dose showed similar but less consistent trends in this group. In contrast, no significant associations were observed in the low‐risk group (Figure 3A, Figure S4).

FIGURE 3.

FIGURE 3

Restricted cubic spline analyses demonstrating nonlinear associations between cryopreserved total nucleated cell (TNC) dose, CD34+ cell dose and CFU‐GM dose and clinical outcomes, including disease‐free survival (DFS) (A), relapse (B) and non‐relapse mortality (NRM) (C), following single‐unit cord blood transplantation (CBT), stratified by low‐risk and high‐risk myelodysplastic syndrome (MDS). Solid lines represent adjusted hazard ratios, and shaded areas indicate 95% confidence intervals.

Relapse and non‐relapse mortality

In univariate analyses, no cord blood unit characteristics or donor–recipient compatibility factors were significantly associated with relapse in either the low‐risk or high‐risk groups (Figure 4). In multivariable analysis, a CD34+ cell dose of 0.61–0.81 × 105/kg (Q2) was associated with a lower risk of relapse in the high‐risk group (HR 0.73, 95% CI 0.55–0.98), whereas HLA serological one‐locus mismatch was associated with a higher risk of relapse (HR 1.24, 95% CI 1.00–1.55) (Figure 2B). The interaction terms between disease risk and CD34+ cell dose (Q2) was significant for relapse (p for interaction 0.150) (Figure 2B), indicating that the prognostic impact of CD34+ cell dose differs according to disease risk.

FIGURE 4.

FIGURE 4

The cumulative incidence of relapse following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

In univariate analyses using Gray's test, no cord blood characteristics or compatibility factors were significantly associated with non‐relapse mortality (NRM) in either group (Figure S5). In multivariable analysis, a higher TNC dose (≥3.14 × 107/kg [Q4]) was associated with lower NRM in the high‐risk group (HR 0.67, 95% CI 0.50–0.90). In addition, HLA serological matching was associated with lower NRM (HR 0.54, 95% CI 0.33–0.91) (Figure S3B). No variables were significantly associated with NRM in the low‐risk group (Figure S3B).

Restricted cubic spline analyses demonstrated that higher TNC and CD34+ cell doses were associated with a lower risk of relapse in the high‐risk group, with CD34+ cell dose also showing a significant association with NRM. In contrast, CFU‐GM dose showed weaker or non‐significant associations with relapse and NRM. No significant associations between cord blood cell doses and relapse or NRM were observed in the low‐risk group (Figure 3B,C).

Haematopoietic recovery

We evaluated factors associated with neutrophil and platelet engraftment separately in the low‐risk and high‐risk groups. In univariate analyses using Gray's test, higher TNC dose, CD34+ cell dose and CFU‐GM count were consistently associated with improved neutrophil engraftment in both groups. In the low‐risk group, ABO compatibility was additionally associated with neutrophil recovery, whereas donor–recipient sex compatibility was significant in the high‐risk group (Figure S6). In multivariable analyses, higher TNC dose (Q2–Q4 and continuous), higher CD34+ cell dose (Q3–Q4) and higher CFU‐GM count (Q2–Q4 and continuous) were independently associated with improved neutrophil engraftment in both groups (Table S1). In the low‐risk group, HLA two‐allele mismatch (HR 1.41, 95% CI 1.07–1.87; p for interaction = 0.051) and major/minor ABO mismatch (HR 1.44, 95% CI 1.12–1.86; p for interaction = 0.012) were associated with faster neutrophil recovery. In contrast, in the high‐risk group, HLA 0–1 allele mismatch was associated with improved neutrophil engraftment (HR 1.30, 95% CI 1.05–1.61; p for interaction = 0.110) (Table S1).

For platelet engraftment, univariate analyses showed that higher TNC dose, CD34+ cell dose and CFU‐GM count were significantly associated with improved recovery in both groups, while ABO compatibility was additionally significant in the high‐risk group (Figure S7). In multivariable analyses, higher TNC dose (Q3–Q4 and continuous), higher CD34+ cell dose (Q3–Q4) and higher CFU‐GM count (Q3–Q4) were independently associated with improved platelet engraftment in both groups (Table S1).

Acute and chronic graft‐versus‐host disease

In univariate analyses using Gray's test, HLA serological mismatch (p = 0.028) and HLA allele mismatch (p = 0.019) were significantly associated with grades II–IV acute graft‐versus‐host disease (GVHD) in the high‐risk group (Figures S8 and S9). In multivariable analysis, male‐to‐female donor–recipient sex incompatibility was independently associated with a higher risk of grades II–IV acute GVHD in the high‐risk group (HR 1.31, 95% CI 1.02–1.68; p for interaction = 0.140) (Table S2).

In contrast, no cord blood unit characteristics or donor–recipient compatibility factors were significantly associated with chronic GVHD in univariate analyses in either risk group (Figure S10). In multivariable analysis, HLA 0–1 allele mismatch was associated with a higher risk of chronic GVHD in the low‐risk group (HR 1.91, 95% CI 1.04–3.53; p for interaction = 0.096) (Table S2).

Subgroup analysis according to transplant era

We further evaluated the impact of CD34+ cell dose on DFS according to transplant era (1999–2016 vs. 2017–2023). In univariate analyses, the favourable effect of higher CD34+ cell dose on DFS in the high‐risk group appeared more pronounced in the recent era than in the earlier era (Figure S11). In multivariable analyses restricted to the high‐risk group, a CD34+ cell dose of 0.82–1.10 × 105/kg (Q3) was significantly associated with improved DFS in the recent era (HR 0.61, 95% CI 0.46–0.82), whereas no significant association was observed in the earlier era (HR 0.91, 95% CI 0.69–1.21; p for interaction = 0.057). These findings suggest that the beneficial impact of higher CD34+ cell dose on DFS in patients with high‐risk MDS has become more pronounced in the recent transplant era.

DISCUSSION

This represents the largest nationwide retrospective study of adult patients with MDS undergoing first single‐unit unrelated CBT. We demonstrated that the prognostic significance of cord blood graft characteristics differs substantially according to disease risk at transplantation. While no cord blood–related variables were associated with DFS or OS in patients with low‐risk MDS, several graft characteristics—including cryopreserved TNC dose, CD34+ cell dose, CFU‐GM dose, HLA serological compatibility and donor–recipient sex compatibility—were independently associated with DFS in patients with high‐risk MDS. Restricted cubic spline Cox regression further demonstrated a significant non‐linear association between CD34+ cell dose and both DFS and relapse in the high‐risk group. These findings suggest that cord blood unit selection has limited impact on survival in low‐risk MDS but may play a clinically meaningful role in improving outcomes in patients with high‐risk disease.

A key finding of this study is that a lower cryopreserved CD34+ cell dose (<0.61 × 105/kg) was associated with inferior DFS exclusively in patients with high‐risk MDS. Although CD34+ cell dose is a well‐established determinant of haematopoietic recovery after CBT, its impact on long‐term survival has been inconsistent across heterogeneous adult cohorts, 13 , 14 in contrast to more consistent findings in paediatric populations. 35 , 36 In our analysis, restricted cubic spline Cox regression demonstrated that lower stem cell dose was associated with a higher risk of treatment failure in high‐risk MDS, potentially driven by an increased risk of relapse. This observation is consistent with our previous findings in non‐remission acute myeloid leukaemia. 37 In contrast, patients with low‐risk MDS may better tolerate delayed haematopoietic recovery without compromising long‐term disease control, thereby attenuating the survival impact of CD34+ cell dose. Furthermore, a higher CFU‐GM dose was independently associated with improved DFS in high‐risk MDS. As CFU‐GM reflects the functional progenitor capacity of the graft, it may better capture graft quality than TNC or CD34+ cell dose alone. 38 The beneficial effect of CFU‐GM observed in this study supports prior reports demonstrating its association with faster engraftment 13 , 14 , 15 , 16 , 38 and extends these findings by showing a survival advantage specifically in high‐risk MDS. Consistent with previous studies, 13 , 14 , 15 , 16 , 38 higher cryopreserved cell doses were strongly associated with faster neutrophil and platelet recovery in both risk groups. However, improved haematopoietic recovery did not uniformly translate into better survival, particularly in low‐risk MDS. This dissociation suggests that engraftment kinetics alone are insufficient as surrogate markers for long‐term outcomes. Collectively, these findings indicate that functional graft parameters capture biologically relevant features of cord blood units and may help refine unit selection strategies, particularly for patients with high‐risk MDS.

Although cord blood unit selection in Japan during the study period relied on low‐resolution HLA typing (HLA‐A, ‐B and ‐DR), selection in the United States and the United Kingdom is based on high‐resolution HLA matching, including HLA‐A, ‐B, ‐C and ‐DRB1. 10 , 11 , 12 In our study, HLA compatibility in serum and allele‐levels also demonstrated risk‐dependent prognostic significance. In high‐risk MDS, HLA serological matching was associated with reduced NRM, whereas HLA serological 1 locus mismatch was independently associated with inferior DFS, driven by an increased risk of relapse. However, no such association was observed in low‐risk disease. These results suggest that in high‐risk MDS, higher relapse rather than NRM contributes to worse DFS, making HLA serum compatibility a critical determinant of survival outcome. On the other hand, HLA compatibility at the allele‐level was not associated with relapse in either risk group, which differs from previous findings showing that better HLA allele matching was associated with an increased risk of relapse in patients with acute leukaemia and MDS. 14 , 18 , 19 By contrast, consistent with previous studies, 14 , 17 , 19 HLA 0–1 allele mismatch was associated with neutrophil engraftment only in the high‐risk group. These findings support the concept that the effects of HLA allele matching on relapse and engraftment after CBT may differ across a range of disease types and disease statuses.

Female‐to‐male donor–recipient sex incompatibility was associated with inferior DFS in patients with high‐risk MDS. In contrast to allogeneic peripheral blood stem cell transplantation (PBSCT), where donor–recipient sex compatibility has well‐established prognostic implications, prior studies have reported a limited impact of sex compatibility in the setting of CBT, 39 , 40 which differs from our findings. Notably, in our cohort, donor–recipient sex compatibility was not significantly associated with relapse, NRM or OS, regardless of MDS risk status. These results suggest that the prognostic impact of donor–recipient sex compatibility in CBT for MDS is modest and may be largely confined to DFS in high‐risk disease, and overall less pronounced than that observed in allogeneic PBSCT.

Patients with high‐risk MDS have a greater disease burden and more aggressive biology, making them more dependent on early graft‐versus‐MDS effects for disease control, 41 which may be enhanced by higher CD34+ cell dose through improved engraftment and immune recovery. These patients are also more vulnerable to transplant‐related complications, linking graft characteristics to NRM. In contrast, patients with low‐risk MDS generally have a lower disease burden and slower disease kinetics, allowing for more stable disease control that is less dependent on early post‐transplant immune effects. Consequently, the impact of graft‐related variables on both relapse and NRM may be attenuated in low‐risk group.

This study has several limitations inherent to its retrospective design. Although we adjusted for a wide range of clinical and transplant‐related variables, residual confounding from unmeasured factors cannot be excluded. These include genetic features of MDS (e.g. TP53 or ASXL1 mutations), 42 disease risk at transplantation as defined by IPSS or IPSS‐R, 43 extended HLA typing (e.g., HLA‐C, ‐DP, ‐DQ and ‐DRB3/4/5), 44 , 45 killer immunoglobulin‐like receptor (KIR) mismatch, 46 and centre‐specific supportive care practices. 47 , 48 In particular, IPSS or IPSS‐R assessed at diagnosis may not accurately reflect disease status at the time of CBT, given the substantial variability in the interval from diagnosis to transplantation. As such, these scores may be suboptimal for evaluating the impact of graft characteristics on transplant outcomes in this setting. Despite these limitations, the large sample size, uniform use of single‐unit CBT and comprehensive characterization of graft variables enhance the robustness and generalizability of our findings regarding the prognostic impact of cord blood unit characteristics in low‐risk and high‐risk MDS. Based on these results, we propose a risk‐adapted approach to cord blood unit selection in adult MDS. In high‐risk disease, cell dose—particularly CD34+ cell dose—should be prioritized, even at the expense of slightly lower HLA matching within acceptable limits. In contrast, in low‐risk MDS, both cell dose and HLA compatibility should be considered, given their relatively balanced and limited impact on transplant outcomes. This approach may help refine decision‐making when multiple suitable cord blood units are available.

In conclusion, the prognostic impact of cord blood unit characteristics after single‐unit CBT in adult MDS is strongly dependent on disease risk at transplantation. While graft selection appears to have limited influence on survival in low‐risk MDS, optimization of graft characteristics—particularly CD34+ cell dose—may improve outcomes in high‐risk disease. These findings support a risk‐adapted approach to cord blood unit selection, with greater emphasis on cell dose in high‐risk MDS to improve transplant outcomes.

AUTHOR CONTRIBUTIONS

Machiko Fujioka: Resources; writing – review and editing. Hiroki Hosoi: Resources; writing – review and editing. Masatsugu Tanaka: Resources. Kyoko Fuse: Resources; writing – review and editing. Noriko Doki: Resources. Fumihiko Ishimaru: Resources. Tatsuya Suwabe: Resources; writing – review and editing. Atsushi Wake: Resources. Koji Kawamura: Resources. Naoyuki Uchida: Resources. Takaaki Konuma: Methodology; supervision; formal analysis; investigation; project administration; writing – original draft; conceptualization. Junya Kanda: Resources. Yoshiko Atsuta: Funding acquisition; resources. Kazuto Ogura: Resources. Satoshi Takahashi: Resources. Makoto Onizuka: Resources. Takeshi Maeda: Resources. Toshimitsu Ueki: Resources. Masatoshi Sakurai: Resources. Naoyuki Anzai: Resources. Marie Ohbiki: Resources. Yasufumi Uehara: Resources. Yoshiko Matsuhashi: Resources. Hidehiro Itonaga: Resources; writing – review and editing.

CONFLICT OF INTEREST STATEMENT

MS owns stock in Celaid Therapeutics, outside the submitted work. The other authors declare no competing interests.

Supporting information

Table S1. Multivariate analysis for neutrophil and platelet engraftment according to cord blood characteristics following single‐unit CBT for low‐risk and high‐risk MDS.

Table S2. Multivariate analysis for acute and chronic GVHD according to cord blood characteristics following single‐unit CBT for low‐risk and high‐risk MDS.

Figure S1. The probability of overall survival following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S2. The probability of disease‐free survival (A), and overall survival (B), and the cumulative incidence of relapse (C), and non‐relapse mortality (NRM) (D) following single‐unit CBT for low‐risk and high‐risk MDS based on HLA serum mismatch.

Figure S3. Forest plots of adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for overall mortality (A) and for non‐relapse mortality (NRM) (B) according to cord blood characteristics following single‐unit CBT for low‐risk and high‐risk MDS.

Figure S4. Restricted cubic spline analyses demonstrating non‐linear associations between cryopreserved total nucleated cell (TNC) dose, CD34+ cell dose and CFU‐GM dose and overall survival (OS) following single‐unit cord blood transplantation (CBT), stratified by low‐risk and high‐risk myelodysplastic syndrome (MDS). Solid lines represent adjusted hazard ratios, and shaded areas indicate 95% confidence intervals.

Figure S5. The cumulative incidence of non‐relapse mortality (NRM) following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S6. The cumulative incidence of neutrophil engraftment following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S7. The cumulative incidence of platelet engraftment following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S8. The cumulative incidence of grades II–IV acute GVHD following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S9. The cumulative incidence of neutrophil engraftment (A), platelet engraftment (B), grades II–IV acute GVHD (C) and chronic GVHD (D).

Figure S10. The cumulative incidence of chronic GVHD following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F) following single‐unit CBT for low‐risk and high‐risk MDS based on HLA serum mismatch.

Figure S11. The probability of disease‐free survival following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved CD34+ cell dose according to the transplant era.

BJH-209-2191-s001.zip (9.5MB, zip)

ACKNOWLEDGEMENTS

We thank all of the physicians and staff at the centres who provided the clinical data to the Transplant Registry Unified Management Program (TRUMP) of the Japanese Society for Transplantation and Cellular Therapy (JSTCT) and the Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT). This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from Japan Agency for Medical Research and Development, AMED under grant 18ek0510023h0002. The authors also acknowledge the use of ChatGPT (OpenAI) for assistance with English language editing. The authors take full responsibility for the content of this manuscript.

DATA AVAILABILITY STATEMENT

The data of this study are not publicly available due to ethical restrictions that exceed the scope of the recipient/donor's consent for research use in the registry. Data may be available from the corresponding author upon reasonable request and with permission of the JSTCT/JDCHCT.

REFERENCES

  • 1. Robin M, Sanz GF, Ionescu I, Rio B, Sirvent A, Renaud M, et al. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia. 2011;25(1):75–81. 10.1038/leu.2010.219 [DOI] [PubMed] [Google Scholar]
  • 2. Gerds AT, Woo Ahn K, Hu ZH, Abdel‐Azim H, Akpek G, Aljurf M, et al. Outcomes after umbilical cord blood transplantation for myelodysplastic syndromes. Biol Blood Marrow Transplant. 2017;23(6):971–979. 10.1016/j.bbmt.2017.03.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Ishiyama K, Aoki J, Itonaga H, Uchida N, Takahashi S, Ohno Y, et al. Graft‐versus‐MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese data Center for Hematopoietic Cell Transplantation. Blood Cancer J. 2019;9(3):31. 10.1038/s41408-019-0192-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Konuma T, Shimomura Y, Ishiyama K, Ara T, Nakamae H, Hiramoto N, et al. Haploidentical transplantation with post‐transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: a retrospective study from the adult myelodysplastic syndrome working Group of the Japanese Society for transplantation and cellular therapy (JSTCT). Am J Hematol. 2022;97(12):E447–E450. 10.1002/ajh.26722 [DOI] [PubMed] [Google Scholar]
  • 5. Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, et al. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome? Bone Marrow Transplant. 2023;58(8):893–906. 10.1038/s41409-023-01997-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Konuma T, Itonaga H, Shimomura Y, Fujioka M, Aoki K, Uchida N, et al. Single‐unit unrelated cord blood transplantation versus HLA‐matched sibling transplantation in adults with advanced myelodysplastic syndrome: a registry‐based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy. Hematol Oncol. 2024;42(1):e3217. 10.1002/hon.3217 [DOI] [PubMed] [Google Scholar]
  • 7. Konuma T, Itonaga H, Ishiyama K, Hamamura A, Uchida N, Ozawa Y, et al. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a real‐world registry study in Japan. Am J Hematol. 2023;98(4):E68–E71. 10.1002/ajh.26839 [DOI] [PubMed] [Google Scholar]
  • 8. Konuma T, Kanda J, Inamoto Y, Hayashi H, Kobayashi S, Uchida N, et al. Improvement of early mortality in single‐unit cord blood transplantation for Japanese adults from 1998 to 2017. Am J Hematol. 2020;95(4):343–353. 10.1002/ajh.25705 [DOI] [PubMed] [Google Scholar]
  • 9. Konuma T, Kanda J, Uchida N, Tanaka M, Kimura F, Nakasone H, et al. Has early mortality following single‐unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan. Br J Haematol. 2025;207(5):2026–2040. 10.1111/bjh.70099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2016;172(3):360–370. 10.1111/bjh.13802 [DOI] [PubMed] [Google Scholar]
  • 11. Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134(12):924–934. 10.1182/blood.2019001212 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Politikos I, Davis E, Nhaissi M, Wagner JE, Brunstein CG, Cohen S, et al. Guidelines for cord blood unit selection. Biol Blood Marrow Transplant. 2020;26(12):2190–2196. 10.1016/j.bbmt.2020.07.030 [DOI] [PubMed] [Google Scholar]
  • 13. Konuma T, Kato S, Oiwa‐Monna M, Tanoue S, Ogawa M, Isobe M, et al. Cryopreserved CD34+ cell dose, but not Total nucleated cell dose, influences hematopoietic recovery and extensive chronic graft‐versus‐host disease after single‐unit cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2017;23(7):1142–1150. 10.1016/j.bbmt.2017.03.036 [DOI] [PubMed] [Google Scholar]
  • 14. Morishima Y, Watanabe‐Okochi N, Kai S, Azuma F, Kimura T, Matsumoto K, et al. Selection of cord blood unit by CD34+ cell and GM‐CFU numbers and allele‐level HLA matching in single cord blood transplantation. Transplant Cell Ther. 2023;29(10):622–631. 10.1016/j.jtct.2023.07.022 [DOI] [PubMed] [Google Scholar]
  • 15. Kuwatsuka Y, Kasajima R, Yamaguchi R, Uchida N, Konuma T, Tanaka M, et al. Machine learning prediction model for neutrophil recovery after unrelated cord blood transplantation. Transplant Cell Ther. 2024;30(4):444.e1–444.e11. 10.1016/j.jtct.2024.02.001 [DOI] [PubMed] [Google Scholar]
  • 16. Watanabe M, Konuma T, Imahashi N, Terakura S, Seo S, Morishima S, et al. Scoring system for optimal cord blood unit selection for single cord blood transplantation. Cytotherapy. 2024;26(3):286–298. 10.1016/j.jcyt.2023.12.001 [DOI] [PubMed] [Google Scholar]
  • 17. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele‐level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123(1):133–140. 10.1182/blood-2013-05-506253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Sanz J, Jaramillo FJ, Planelles D, Montesinos P, Lorenzo I, Moscardó F, et al. Impact on outcomes of human leukocyte antigen matching by allele‐level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2014;20(1):106–110. [PubMed] [Google Scholar]
  • 19. Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, et al. Impact of HLA allele mismatch at HLA‐A, ‐B, ‐C, and ‐DRB1 in single cord blood transplantation. Biol Blood Marrow Transplant. 2020;26(3):519–528. 10.1016/j.bbmt.2019.11.001 [DOI] [PubMed] [Google Scholar]
  • 20. Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA‐related data). Int J Hematol. 2016;103(1):3–10. 10.1007/s12185-015-1894-x [DOI] [PubMed] [Google Scholar]
  • 21. Kanda J. Scripts for TRUMP data analyses. Part II (HLA‐related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103(1):11–19. 10.1007/s12185-015-1907-9 [DOI] [PubMed] [Google Scholar]
  • 22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–199. [PubMed] [Google Scholar]
  • 23. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. 10.1182/blood-2009-03-209262 [DOI] [PubMed] [Google Scholar]
  • 24. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. 10.1182/blood-2016-03-643544 [DOI] [PubMed] [Google Scholar]
  • 25. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088. [PubMed] [Google Scholar]
  • 26. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia‐Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. 10.1182/blood-2012-03-420489 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828. [PubMed] [Google Scholar]
  • 28. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft‐versus‐host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250–259. [PubMed] [Google Scholar]
  • 29. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655. [PubMed] [Google Scholar]
  • 30. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)‐specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. 10.1182/blood-2005-05-2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced‐intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–369. 10.1016/j.bbmt.2008.12.497 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Watanabe‐Okochi N, Odajima T, Ito M, Yamada N, Shinozaki M, Minemoto M, et al. Criteria for storage of cord blood units at Japan's largest cord blood bank. Vox Sang. 2024;119(8):867–877. 10.1111/vox.13687 [DOI] [PubMed] [Google Scholar]
  • 33. Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 2020;55(4):675–680. 10.1038/s41409-019-0679-x [DOI] [PubMed] [Google Scholar]
  • 34. Kanda Y. Investigation of the freely available easy‐to‐use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. 10.1038/bmt.2012.244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment‐related mortality and survival. Blood. 2002;100(5):1611–1618. 10.1182/blood-2002-01-0294 [DOI] [PubMed] [Google Scholar]
  • 36. Ishida H, Kawahara Y, Tomizawa D, Okamoto Y, Hama A, Cho Y, et al. A higher CD34+cell dose correlates with better event‐free survival after KIR‐ligand mismatched cord blood transplantation for childhood acute myeloid leukemia. J Hematol Oncol. 2024;17(1):24. 10.1186/s13045-024-01548-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Konuma T, Shimomura Y, Yamasaki S, Kondo T, Uchida N, Tanaka M, et al. Can cord blood unit selection improve outcomes after single‐unit unrelated cord blood transplantation for non‐remission acute myeloid leukemia? Transplant Cell Ther. 2026;32(5):592–608. 10.1016/j.jtct.2026.02.050 [DOI] [PubMed] [Google Scholar]
  • 38. Hussein E, DeFor T, Wagner JE, Sumstad D, Brunstein CG, McKenna DH. Evaluation of post‐thaw CFU‐GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant. Transfusion. 2020;60(1):144–154. 10.1111/trf.15592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Konuma T, Kato S, Ooi J, Oiwa‐Monna M, Ebihara Y, Mochizuki S, et al. Impact of sex incompatibility on the outcome of single‐unit cord blood transplantation for adult patients with hematological malignancies. Bone Marrow Transplant. 2014;49(5):634–639. 10.1038/bmt.2014.10 [DOI] [PubMed] [Google Scholar]
  • 40. Tamaki M, Akahoshi Y, Okada Y, Uchida N, Tanaka M, Doki N, et al. Unrelated female‐to‐male bone marrow transplantation would be preferred over cord blood transplantation in male patients. Cytotherapy. 2023;25(11):1220–1228. 10.1016/j.jcyt.2023.06.002 [DOI] [PubMed] [Google Scholar]
  • 41. Konuma T, Ishiyama K, Igarashi A, Uchida N, Ozawa Y, Fukuda T, et al. Effects of acute and chronic graft‐versus‐myelodysplastic syndrome on long‐term outcomes following allogeneic hematopoietic cell transplantation. Clin Cancer Res. 2020;26(24):6483–6493. 10.1158/1078-0432.CCR-20-1104 [DOI] [PubMed] [Google Scholar]
  • 42. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem‐cell transplantation. N Engl J Med. 2017;376(6):536–547. 10.1056/NEJMoa1611604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS‐R. Blood. 2014;123(15):2333–2342. 10.1182/blood-2013-12-542720 [DOI] [PubMed] [Google Scholar]
  • 44. Yabe T, Azuma F, Kashiwase K, Matsumoto K, Orihara T, Yabe H, et al. HLA‐DPB1 mismatch induces a graft‐versus‐leukemia effect without severe acute GVHD after single‐unit umbilical cord blood transplantation. Leukemia. 2018;32(1):168–175. 10.1038/leu.2017.202 [DOI] [PubMed] [Google Scholar]
  • 45. Osada M, Yamamoto H, Watanabe O, Yamaguchi K, Kageyama K, Kaji D, et al. Lymphocyte crossmatch testing or donor HLA‐DP and ‐DQ allele typing effectiveness in single cord blood transplantation for patients with anti‐HLA antibodies other than against HLA‐A, ‐B, ‐C, and ‐DRB1. Transplant Cell Ther. 2024;30(7):696.e1–696.e14. 10.1016/j.jtct.2024.04.011 [DOI] [PubMed] [Google Scholar]
  • 46. Yokoyama H, Kanaya M, Iemura T, Hirayama M, Yamasaki S, Kondo T, et al. Improved outcomes of single‐unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin‐like receptor 2DL1‐ligand mismatch. Bone Marrow Transplant. 2022;57(7):1171–1179. 10.1038/s41409-022-01700-y [DOI] [PubMed] [Google Scholar]
  • 47. Shouval R, Ruggeri A, Labopin M, Mohty M, Sanz G, Michel G, et al. An integrative scoring system for survival prediction following umbilical cord blood transplantation in acute leukemia. Clin Cancer Res. 2017;23(21):6478–6486. 10.1158/1078-0432.CCR-17-0489 [DOI] [PubMed] [Google Scholar]
  • 48. Yanada M, Yano S, Kuwatsuka Y, Kawamura K, Fukuda T, Ichinohe T, et al. The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Bone Marrow Transplant. 2024;59(4):541–549. 10.1038/s41409-024-02222-5 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table S1. Multivariate analysis for neutrophil and platelet engraftment according to cord blood characteristics following single‐unit CBT for low‐risk and high‐risk MDS.

Table S2. Multivariate analysis for acute and chronic GVHD according to cord blood characteristics following single‐unit CBT for low‐risk and high‐risk MDS.

Figure S1. The probability of overall survival following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S2. The probability of disease‐free survival (A), and overall survival (B), and the cumulative incidence of relapse (C), and non‐relapse mortality (NRM) (D) following single‐unit CBT for low‐risk and high‐risk MDS based on HLA serum mismatch.

Figure S3. Forest plots of adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for overall mortality (A) and for non‐relapse mortality (NRM) (B) according to cord blood characteristics following single‐unit CBT for low‐risk and high‐risk MDS.

Figure S4. Restricted cubic spline analyses demonstrating non‐linear associations between cryopreserved total nucleated cell (TNC) dose, CD34+ cell dose and CFU‐GM dose and overall survival (OS) following single‐unit cord blood transplantation (CBT), stratified by low‐risk and high‐risk myelodysplastic syndrome (MDS). Solid lines represent adjusted hazard ratios, and shaded areas indicate 95% confidence intervals.

Figure S5. The cumulative incidence of non‐relapse mortality (NRM) following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S6. The cumulative incidence of neutrophil engraftment following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S7. The cumulative incidence of platelet engraftment following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S8. The cumulative incidence of grades II–IV acute GVHD following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F).

Figure S9. The cumulative incidence of neutrophil engraftment (A), platelet engraftment (B), grades II–IV acute GVHD (C) and chronic GVHD (D).

Figure S10. The cumulative incidence of chronic GVHD following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved TNC dose (A), CD34+ cell dose (B), CFU‐GM (C), HLA allele mismatch (D), sex compatibility (E) and ABO compatibility (F) following single‐unit CBT for low‐risk and high‐risk MDS based on HLA serum mismatch.

Figure S11. The probability of disease‐free survival following single‐unit CBT for low‐risk and high‐risk MDS based on cryopreserved CD34+ cell dose according to the transplant era.

BJH-209-2191-s001.zip (9.5MB, zip)

Data Availability Statement

The data of this study are not publicly available due to ethical restrictions that exceed the scope of the recipient/donor's consent for research use in the registry. Data may be available from the corresponding author upon reasonable request and with permission of the JSTCT/JDCHCT.


Articles from British Journal of Haematology are provided here courtesy of Wiley

RESOURCES